Natalie [Analyst]'s questions to Cytokinetics Inc (CYTK) leadership • Q1 2025
Question
Natalie from UBS asked for commentary on competitor Edgewise's recent clinical data and how their ejection fraction measurements might differ if taken at peak versus trough.
Answer
Robert I. Blum, President and CEO, refrained from making direct comparisons with an early-stage investigational drug. Fady Malik, EVP of R&D, noted that for aficamten, the peak-to-trough ejection fraction difference is minimal. He acknowledged that any drug's measured effect would likely be greater at peak concentration but stated it is difficult to speculate on the exact magnitude for another compound.